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Estrogen receptors (ERs) and the aryl hydrocarbon receptor (AhR) are ligand activated transcription factors
and members of the nuclear receptor and bHLH-PAS superfamilies, respectively. AhR is involved in xenobiotic
metabolism and in mediating the toxic effects of dioxin-like compounds. Crosstalk has been observed among
AhR and nuclear receptors, but has been most well studied with respect to ER signaling. Activated AhR
inhibits ER activity through a number of different mechanisms, whereas ERα has been reported to have a
positive role in AhR signaling. Here we will discuss recent data revealing that dioxin bound AhR recruits ERα
to AhR regulated genes.We will also consider the implications of ER recruitment to AhR target genes on ER
and AhR signaling.
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Introduction
Estrogen receptor α (ERα) and ERβ, and related steroid
hormone receptors mediate the signals of small
hydrophobic molecules by acting as ligand-dependent
transcription factors. Ligand binding induces receptor
homodimerization, DNA binding to estrogen response
elements in the promoter regions of target genes,
recruitment of coregulators and changes in transcription.
Although ligand binding is an important mechanism of
nuclear receptor activation, many receptors, including
ERα and ERβ, are activated by growth hormones,
kinases, and other hormone-bound steroid receptors and
transcription factors [Kato et al., 1995; Kousteni et al.,
2001].The aryl hydrocarbon receptor (AhR) is a member
of the basic-helix-loop-helix Per (Period)–ARNT (aryl
hydrocarbon nuclear translocator)–SIM (single minded)
(bHLH-PAS) family [Gu et al., 2000]. Upon ligand binding,
the AhR translocates from the cytoplasm to the nucleus
where it binds its dimerization partner ARNT.The
activated AhR/ARNT heterodimer complex binds to its
cognate DNA sequences, termed xenobiotic response
elements (XREs), and activates the expression of AhR
target genes, such as cytochrome P4501A1 (CYP1A1)
and CYP1B1 [Hankinson, 1995]. AhR null animals reveal
that the AhR mediates most, if not all, of the toxic effects
of 2,3,7,8-tetrachlorodibenzo-[p]-dioxin (TCDD) [Lahvis
and Bradfield, 1998]. Although its physiological role is
unknown, the AhR has been shown to play an important
role in liver development and female reproduction [Baba
et al., 2005; Schmidt et al., 1996].
Inhibitory crosstalk between AhR and
ER signaling
Inhibitory crosstalk between the AhR and ER signaling
was suggested by early experiments examining the
long-term effects of TCDD treatment in Sprague Dawley
rats [Kociba et al., 1978]. Among the findings, were the
observations that the incidences of both mammary and
uterine tumors were decreased in female rats [Kociba et
al., 1978], which were supported by other reports
demonstrating that TCDD inhibits the formation of
7,2-dimethylbenz[a]anthracene (DMBA) induced
mammary tumors [Holcomb and Safe, 1994]. Several
studies have since reported that activated AhR inhibits
the expression of E2 induced genes [Safe and Wormke,
2003].The precise molecular mechanisms for this
crosstalk are unclear, and may be a combination of
several different mechanisms (Figure 1).
AhR agonist dependent recruitment of
ERα to AhR regulated promoters
Recent data from our group reveals that in the absence
of 17β-estradiol (E2) TCDD bound AhR recruits ERα to
AhR regulated genes, CYP1A1 and CYP1B1 [Matthews
et al., 2005].This recruitment most likely occurs through
direct protein/protein interactions between ERα and AhR
[Beischlag and Perdew, 2005; Ohtake et al., 2003].
Promoter occupancy by ERα at CYP1A1 was increased
by cotreatment with TCDD and E2; however, E2 treatment
only enhanced TCDD-induced CYP1A1 regulated reporter
gene activity and not endogenous CYP1A1 mRNA levels.
The molecular mechanisms governing the increase in
recruitment of ERα by cotreatment of TCDD and E2 are
unclear, but may be a combination of E2-induced
homodimerization resulting in recruitment of ERα
homodimer rather than the monomer and that the
conformational change of ERα induced by E2 better
exposes the epitope interaction surfaces allowing
improved antibody interaction. Our data support the novel
scenario that active AhR can redirect ER from ER target
genes to AhR target genes, suggesting that AhR can
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Perspective  Nuclear Receptor Signaling  |  The Open Access Journal of the Nuclear Receptor Signaling AtlasFigure 1.  Proposed mechanisms of crosstalk between AhR and ER signaling pathways AhR has been reported to inhibit ER activity through
a combination of several different mechanisms: direct inhibition by the activated AhR/ARNT heterodimer through binding to inhibitory XRE (iXRE)
present in ER target genes; squelching of shared coactivators, including ARNT; synthesis of an unknown inhibitory protein; increased proteasomal
degradation of ER; and altered estrogen synthesis/metabolism through increase in aromatase, cytochromeP450 1A1 and 1B1 expression. Modified
from Safe and Wormke, 2003.
regulate ERα protein levels and consequently estrogenic
responses [Matthews et al., 2005]. For example, TCDD
treatment is known to reduce the protein levels of ERα,
which are dependent on proteasome activity [Wormke et
al., 2003]; the recruitment of ERα to the AhR complex,
away from ER regulated genes may serve as a
mechanism to regulate ERα protein levels (Figure 2).The
signals that recruit ERα to the activated AhR complex
are unknown, and may include the activation of other
signaling pathways, such as kinases, since the ERα AF1
is needed for recruitment to and interaction with the AhR
complex [Ohtake et al., 2003] (Wihlén et al., in
preparation).
Figure 2.  Modulation of ER and AhR signaling via dioxin dependent
interaction of ER with AhR The association of ER with activated AhR
can be viewed as two separate pathways. 1. Activated AhR recruits
unliganded or liganded ERα away from ER regulated genes to AhR
regulated genes, inhibiting estrogen signaling.The shuttling via the AhR
may serve as a mechanism to regulate ER protein levels. 2. ERα has
been shown to modulate AhR-dependent transcription, suggesting that
ERα is an important regulator of AhR activity.
Is AhR a coregulator of ER-dependent
transcription?
3-Methylcholanthrene, a polycyclic aromatic hydrocarbon
(PAH) AhR agonist has been reported to activate AhR
such that it interacts with unliganded ERα and the entire
AhR/ERα complex is recruited to estrogen responsive
genes, suggesting that ER signaling is modulated by
co-regulatory-like functions of AhR [Ohtake et al., 2003].
However, PAHs can be metabolized to relatively potent
estrogenic compounds and independent studies have
reported estrogenic effects of 3MC and other AhR
agonists in the absence of AhR [Pearce et al., 2004;
Shipley and Waxman, 2005]. AhR agonists, such as 3MC,
have recently been shown to directly activate ERα, and
are suggested to represent a new class of mixed AhR/ER
agonists [Abdelrahim et al., 2006]. Moreover, ARNT
directly interacts with ERs and has been shown by
transient transfection to coactivate ER-dependent gene
expression [Brunnberg et al., 2003].
ERα is a ligand activated modulator of
AhR-dependent transcription
Our studies confirm a proposed “hijacking” of ERα by
activated AhR [Brosens and Parker, 2003], but we and
others observe ERα to be present at AhR target genes
[Abdelrahim et al., 2006; Beischlag and Perdew, 2005;
Matthews et al., 2005]. As we have suggested above this
recruitment could have important consequences on ER
signaling, but also reveals an important role for ERα in
AhR-dependent transcription.There are conflicting reports
on the effect of E2 on TCDD-induced expression of AhR
target genes. Some studies report an inhibition [Beischlag
and Perdew, 2005; Kharat and Saatcioglu, 1996],
whereas we and others observe a slight activation or no
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differences may be due to different cell culture conditions,
cell passage, serum lots and treatment regimes.The
observation that transfection of ERα into ER negative
breast cancer cell lines restores AhR responsiveness as
determined by CYP1A1 induction, suggests a positive
role for ER in AhR responses [Thomsen et al., 1994].
Consistent with ERα positively influencing AhR activity
are our findings that short hairpin RNA (shRNA) mediated
knockdown of ERα expression significantly reduced
TCDD-induced CYP1A1 expression, whereas cotreatment
with E2 had no further effect [Matthews et al., 2005].
Stable knockdown of ERα in HC11 mouse mammary
cells confirmed an important role for ERα in AhR
agonist-induced CYP1A1 expression, although no
reduction was observed in induced CYP1B1 expression
(Matthews et al. submitted).These data suggest that ERα
is a promoter-specific modulator of AhR-dependent
transcription, and demonstrate the complexity of crosstalk
between these two receptor pathways (Figure 2).Whether
ERα acts as a coregulator or recruits additional cofactors
that modulate AhR transcription is currently under
investigation and an important area for future research.
The ERα modulation of AhR activity represents a new
mechanism of ERα signaling.The recruitment of ERα by
AhR agonist to CYP1A1 and CYP1B1 and its
enhancement by E2, also leads to the hypothesis that
this process may represent a feedback regulation in
estrogen signaling, since both CYP1B1 and CYP1A1 are
involved in E2 metabolism [Lee et al., 2003].
Conclusions and Future Prospects
Dioxins and compounds that mimic the activities of
estrogen are found throughout our environment, and
exposure to these compounds has been suggested to
increase the risk of many hormone related diseases
(“endocrine disruption”). Despite many studies our
understanding of the molecular mechanisms of AhR and
ER crosstalk is far from complete.We believe that the
AhR agonist dependent association of ERα with AhR
represents an important mechanism mediating inhibitory
crosstalk between AhR and ER signaling pathways, but
also a new mechanism of ER action. Some of the major
future challenges are to identify the regulatory signals
that cause ER to interact with AhR and to confirm that
ERs are present at AhR target promoters in vivo. Current
data would suggest that AhR influences ERβ signaling
in a similar manner to ERα signaling; however, little is
known about how AhR influences ERβ activity and vice
versa. It will also be important to determine if ERα and/or
ERβ are recruited to all AhR target genes or restricted to
the CYP1A1 and 1B1 promoters. Studies of cell-based
and genetically modified animal models will be important
in assessing the physiological importance of crosstalk
between these receptor systems and in uncovering
potential ER subtype specific regulation.
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